Pharmacology Quiz: Anxiolytics And Sedatives
20 questions · exam conditions
0:00
Anxiolytics And SedativesQuestion 1 of 20

A patient with end-stage liver disease requires short-term management of severe anxiety related to their prognosis. The medical team wants to choose a benzodiazepine with the lowest risk of accumulation and toxicity.

The metabolism of which of the following benzodiazepines is least dependent on the hepatic cytochrome P450 system?

Diazepam
Chlordiazepoxide
Clonazepam
Oxazepam
← Back to quizzes

Pharmacology Quiz

Pharmacology Quiz: Anxiolytics And Sedatives

Practice Anxiolytics And Sedatives in Pharmacology with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Anxiolytics And Sedatives, giving you a quick way to practice the rules, question types, and explanations that matter most for Pharmacology.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

A patient with end-stage liver disease requires short-term management of severe anxiety related to their prognosis. The medical team wants to choose a benzodiazepine with the lowest risk of accumulation and toxicity.

The metabolism of which of the following benzodiazepines is least dependent on the hepatic cytochrome P450 system?

  1. Diazepam
  2. Chlordiazepoxide
  3. Clonazepam
  4. Oxazepam (correct answer)
Explanation: Oxazepam, along with Temazepam and Lorazepam (mnemonic 'OTL' or 'Outside The Liver'), are primarily metabolized through phase II glucuronide conjugation directly to inactive metabolites. This pathway is much less affected by liver disease or age compared to the phase I oxidative metabolism (via CYP450 enzymes) that metabolizes diazepam, chlordiazepoxide, and clonazepam. Therefore, oxazepam is a much safer choice in patients with severe hepatic impairment as it is less likely to accumulate and cause excessive sedation.

Question 2

Both benzodiazepines (e.g., diazepam) and barbiturates (e.g., phenobarbital) enhance the effects of GABA at the GABA-A receptor. Which statement accurately describes a key difference in their molecular mechanisms of action?

  1. Benzodiazepines increase the frequency of chloride channel opening, while barbiturates increase the duration of channel opening.
  2. Benzodiazepines act as direct agonists at the GABA binding site, while barbiturates are positive allosteric modulators.
  3. Benzodiazepines require the presence of GABA to exert an effect, while barbiturates can directly open the chloride channel at high concentrations. (correct answer)
  4. Benzodiazepines bind to the alpha subunit, while barbiturates bind to the gamma subunit of the GABA-A receptor complex.
Explanation: This question tests a subtle but critical distinction. Benzodiazepines are positive allosteric modulators that increase the affinity of GABA for its receptor, thereby increasing the frequency of channel opening, but they cannot open the channel without GABA. In contrast, barbiturates also modulate the receptor (increasing the duration of opening) but, at higher, toxic concentrations, they can act as direct GABA-A agonists and open the chloride channel in the absence of GABA. This property contributes to their lower therapeutic index and higher risk of fatal overdose compared to benzodiazepines. Therefore, statement (C) is the most complete and accurate description of this key difference. Statement (A) describes the different modulatory effects but misses the crucial point about GABA-dependence. Statement (B) is incorrect; both are positive allosteric modulators, not direct agonists at therapeutic doses (though barbiturates can be at high doses). Statement (D) is incorrect regarding the binding sites.

Question 3

A 45-year-old patient with a newly diagnosed generalized anxiety disorder also has a documented history of opioid use disorder and is currently stable on buprenorphine maintenance therapy. The clinician is considering initiating an anxiolytic.

What is the most compelling reason to select buspirone over a benzodiazepine for this patient?

  1. Buspirone has a more rapid onset of anxiolytic action compared to benzodiazepines.
  2. Buspirone lacks cross-tolerance with other CNS depressants and has a low abuse potential. (correct answer)
  3. Buspirone potentiates the analgesic effects of buprenorphine, improving overall treatment response.
  4. Buspirone is a potent inhibitor of CYP3A4, which will increase buprenorphine levels and efficacy.
Explanation: In a patient with a history of substance use disorder, the primary concern with benzodiazepines is their potential for misuse, abuse, and dependence. Buspirone is not a controlled substance, lacks reinforcing properties, and does not exhibit cross-tolerance with benzodiazepines or other CNS depressants like opioids and alcohol, making it a much safer choice. Buspirone has a delayed onset of action (2-4 weeks), which is slower than benzodiazepines (A). There is no significant evidence that buspirone potentiates buprenorphine's analgesic effects (C). Buspirone is a substrate, not a potent inhibitor, of CYP3A4 (D); co-administration with CYP3A4 inhibitors can increase buspirone levels, but this is not a therapeutic rationale for its use.

Question 4

A patient taking diazepam 10 mg at bedtime for muscle spasms complains of significant daytime drowsiness and a 'hangover' feeling that impairs his ability to work.

This prolonged sedative effect is primarily attributable to which pharmacokinetic property of diazepam?

  1. Rapid absorption and high bioavailability after oral administration.
  2. Induction of its own metabolism, leading to fluctuating drug levels.
  3. Metabolism into long-acting active metabolites, such as nordiazepam. (correct answer)
  4. Low lipid solubility, resulting in slow clearance from the central nervous system.
Explanation: Diazepam itself has a long half-life, but more importantly, it is metabolized in the liver to several pharmacologically active compounds, most notably nordiazepam (desmethyldiazepam). Nordiazepam has an extremely long half-life (up to 100 hours) and is further metabolized to oxazepam (also active). The accumulation of these long-acting metabolites contributes significantly to the prolonged sedation, cognitive impairment, and 'hangover' effect seen with diazepam. Rapid absorption (A) relates to onset, not duration. Diazepam does not significantly induce its own metabolism (B). It has high, not low, lipid solubility (D), which contributes to its rapid onset but not its prolonged duration.

Question 5

A 72-year-old male with generalized anxiety disorder (GAD) and moderate hepatic impairment (Child-Pugh class B) requires anxiolytic therapy. His past medical history is also significant for chronic obstructive pulmonary disease. He reports no history of alcohol or substance use.

Given this patient's clinical profile, which medication is the most appropriate choice due to its pharmacokinetic properties?

  1. Diazepam, because its long half-life provides consistent anxiolysis and reduces the risk of rebound anxiety.
  2. Buspirone, because its lack of respiratory depression makes it safer in patients with COPD.
  3. Lorazepam, because it undergoes glucuronidation, a metabolic pathway largely preserved in hepatic dysfunction. (correct answer)
  4. Alprazolam, because its rapid onset of action is beneficial for managing acute anxiety episodes in the elderly.
Explanation: Lorazepam, along with oxazepam and temazepam, is primarily metabolized via phase II glucuronidation, which is less affected by hepatic impairment and advanced age compared to the phase I oxidative metabolism (via CYP450 enzymes) that drugs like diazepam and alprazolam undergo. This makes lorazepam a safer choice in this patient. Diazepam (A) is a poor choice due to its reliance on oxidative metabolism and its long-acting active metabolites, which would accumulate in a patient with hepatic impairment, leading to excessive sedation. While buspirone (B) is a reasonable option for GAD and is safer in COPD, the question specifically asks about pharmacokinetic properties in the context of hepatic impairment, making lorazepam the most precise answer. Alprazolam (D) undergoes oxidative metabolism and is generally avoided or used with extreme caution in the elderly and those with hepatic impairment due to increased risk of cognitive side effects and falls.

Question 6

While both buspirone and selective serotonin reuptake inhibitors (SSRIs) are first-line treatments for generalized anxiety disorder, their mechanisms differ. How does buspirone's action as a 5-HT1A partial agonist lead to a different clinical profile compared to SSRIs?

  1. Buspirone provides immediate anxiolysis through direct receptor agonism, unlike the delayed effect of SSRIs.
  2. Buspirone generally lacks the sexual dysfunction side effects commonly associated with increased synaptic serotonin from SSRIs. (correct answer)
  3. Buspirone is also a potent dopamine D2 receptor agonist, providing antidepressant effects superior to those of SSRIs.
  4. Buspirone's partial agonism leads to a higher risk of serotonin syndrome when compared to full agonists like SSRIs.
Explanation: A key clinical advantage of buspirone is its favorable side effect profile compared to SSRIs. SSRIs increase serotonin levels in the synapse, which can lead to stimulation of various serotonin receptor subtypes (e.g., 5-HT2, 5-HT3), causing side effects like sexual dysfunction, GI upset, and insomnia. Buspirone's more selective action as a 5-HT1A partial agonist and D2 antagonist avoids many of these issues, particularly sexual side effects. Buspirone's effect is delayed, not immediate (A). It is a weak dopamine D2 antagonist, not a potent agonist, and is not considered superior to SSRIs for depression (C). As a partial agonist, its intrinsic activity is lower than a full agonist, and it generally carries a lower risk of serotonin syndrome than SSRIs, especially in monotherapy (D).

Question 7

A 68-year-old male has been taking a stable dose of diazepam for anxiety for several years. He is diagnosed with community-acquired pneumonia and is prescribed a 7-day course of clarithromycin. Two weeks later, his family brings him to the clinic, reporting that he has become excessively sedated, confused, and unsteady on his feet.

The patient's new symptoms are most likely the result of an interaction involving which mechanism?

  1. Inhibition of CYP3A4-mediated metabolism of diazepam. (correct answer)
  2. Displacement of diazepam from plasma protein binding sites.
  3. Additive pharmacodynamic effects on the GABA-A receptor.
  4. Induction of glucuronidation pathways leading to accumulation of a toxic metabolite.
Explanation: Diazepam is extensively metabolized by cytochrome P450 enzymes, particularly CYP3A4 and CYP2C19. Clarithromycin is a potent inhibitor of CYP3A4. By inhibiting the primary metabolic pathway of diazepam, clarithromycin causes diazepam and its active metabolites (like nordiazepam) to accumulate, leading to exaggerated CNS depressant effects such as sedation, confusion, and ataxia. While protein binding displacement (B) can occur with some drugs, it is not the primary mechanism for this clinically significant interaction. The interaction is pharmacokinetic (metabolism), not pharmacodynamic (C), as clarithromycin does not act on the GABA-A receptor. Induction of metabolism (D) would decrease drug levels, not increase them, and this interaction involves inhibition, not induction.

Question 8

A patient with a significant fear of flying is prescribed a single dose of a benzodiazepine to be taken one hour before a flight. Which combination of pharmacokinetic properties would be most desirable for this specific indication?

  1. Low lipid solubility and a long elimination half-life.
  2. High lipid solubility and a short elimination half-life. (correct answer)
  3. Metabolism primarily via glucuronidation with no active metabolites.
  4. High plasma protein binding and a large volume of distribution.
Explanation: For acute, situational anxiety like fear of flying, the ideal agent should work quickly and not have lingering effects. High lipid solubility allows the drug to rapidly cross the blood-brain barrier, leading to a fast onset of action. A short elimination half-life ensures that the effects, such as sedation and cognitive impairment, will resolve relatively quickly after the flight, preventing a 'hangover' effect. Low lipid solubility (A) would delay onset. Metabolism via glucuronidation (C) is a favorable property for patients with liver disease but is not the primary determinant for this specific acute use. High protein binding and a large volume of distribution (D) are general pharmacokinetic parameters but do not specifically address the clinical need for rapid onset and short duration.

Question 9

Chlordiazepoxide is a long-acting benzodiazepine frequently used in protocols for managing acute alcohol withdrawal syndrome.

The efficacy of chlordiazepoxide in preventing withdrawal seizures and delirium is primarily due to its ability to:

  1. Block excitatory NMDA receptors that become upregulated during chronic alcohol use.
  2. Act as a substitute for alcohol at the GABA-A receptor, mitigating the effects of GABAergic hypoactivity. (correct answer)
  3. Stimulate the release of dopamine in the nucleus accumbens, reducing cravings and dysphoria.
  4. Inhibit voltage-gated calcium channels, which stabilizes neuronal membranes against hyperexcitability.
Explanation: Chronic alcohol use enhances GABA-A receptor function. In response, the body downregulates these receptors or reduces their sensitivity. When alcohol is abruptly withdrawn, the CNS is left in a state of GABAergic hypoactivity and glutamatergic hyperactivity, leading to withdrawal symptoms like seizures. Benzodiazepines like chlordiazepoxide act on the same GABA-A receptors as alcohol. By providing a substitute source of GABAergic tone, they effectively dampen CNS hyperexcitability and allow the system to gradually re-equilibrate, preventing severe withdrawal manifestations. Benzodiazepines do not primarily block NMDA receptors (A), stimulate dopamine release in the reward pathway (C), or block voltage-gated calcium channels (D); these are mechanisms of other drugs used in addiction medicine.

Question 10

A 72-year-old male with generalized anxiety disorder (GAD) and moderate hepatic impairment (Child-Pugh class B) requires anxiolytic therapy. His past medical history is also significant for chronic obstructive pulmonary disease. He reports no history of alcohol or substance use.

Given this patient's clinical profile, which medication is the most appropriate choice due to its pharmacokinetic properties?

  1. Diazepam, because its long half-life provides consistent anxiolysis and reduces the risk of rebound anxiety.
  2. Buspirone, because its lack of respiratory depression makes it safer in patients with COPD.
  3. Lorazepam, because it undergoes glucuronidation, a metabolic pathway largely preserved in hepatic dysfunction. (correct answer)
  4. Alprazolam, because its rapid onset of action is beneficial for managing acute anxiety episodes in the elderly.
Explanation: Lorazepam, along with oxazepam and temazepam, is primarily metabolized via phase II glucuronidation, which is less affected by hepatic impairment and advanced age compared to the phase I oxidative metabolism (via CYP450 enzymes) that drugs like diazepam and alprazolam undergo. This makes lorazepam a safer choice in this patient. Diazepam (A) is a poor choice due to its reliance on oxidative metabolism and its long-acting active metabolites, which would accumulate in a patient with hepatic impairment, leading to excessive sedation. While buspirone (B) is a reasonable option for GAD and is safer in COPD, the question specifically asks about pharmacokinetic properties in the context of hepatic impairment, making lorazepam the most precise answer. Alprazolam (D) undergoes oxidative metabolism and is generally avoided or used with extreme caution in the elderly and those with hepatic impairment due to increased risk of cognitive side effects and falls.

Question 11

A 34-year-old female has been taking alprazolam 1 mg three times daily for panic disorder for the past year. She reports that for the last few months, she experiences a surge of intense anxiety and irritability about an hour before her next scheduled dose is due.

Which pharmacological principle best explains this patient's recurring symptoms?

  1. Pharmacodynamic tolerance to the anxiolytic effects of alprazolam.
  2. Occurrence of interdose rebound anxiety due to the drug's short half-life. (correct answer)
  3. Formation of a long-acting metabolite that has paradoxical anxiogenic effects.
  4. Downregulation of 5-HT1A receptors as a consequence of chronic GABAergic stimulation.
Explanation: The phenomenon described is interdose rebound anxiety, which is common with short-acting benzodiazepines like alprazolam. As the drug concentration falls below the therapeutic threshold between doses, withdrawal-like symptoms, including anxiety, emerge. Pharmacodynamic tolerance (A) refers to a decreased response to the drug over time, which would likely manifest as a general lack of efficacy rather than a cyclical pattern timed with dosing. Alprazolam does not have a long-acting metabolite with anxiogenic effects (C); its primary metabolites are less active and have short half-lives. Benzodiazepines do not primarily act on 5-HT1A receptors (D); their mechanism is related to GABA-A receptor modulation, and this option incorrectly links two different neurotransmitter systems.

Question 12

A 28-year-old patient with a history of a seizure disorder, well-controlled with chronic clonazepam therapy, is brought to the emergency department with altered mental status after a suspected polysubstance overdose. The attending physician considers administering flumazenil.

What is the most significant potential risk of administering flumazenil to this particular patient?

  1. Precipitation of a hypertensive crisis due to unopposed stimulant effects.
  2. Induction of refractory status epilepticus by reversing the anticonvulsant effect of clonazepam. (correct answer)
  3. Development of serotonin syndrome if an SSRI was also ingested.
  4. Acute respiratory depression as a paradoxical reaction to the antagonist.
Explanation: Flumazenil is a competitive antagonist at the benzodiazepine binding site on the GABA-A receptor. In a patient who is physically dependent on a benzodiazepine for seizure control, the abrupt reversal of the benzodiazepine's anticonvulsant effects can lower the seizure threshold and precipitate severe, difficult-to-treat seizures or status epilepticus. This is a major contraindication for its use. While flumazenil can unmask the effects of co-ingested stimulants, a hypertensive crisis (A) is not its most specific or feared complication in this context. Flumazenil has no direct effect on serotonin systems and does not cause serotonin syndrome (C). It reverses, rather than causes, respiratory depression (D) when it is due to benzodiazepines alone.

Question 13

A 68-year-old male has been taking a stable dose of diazepam for anxiety for several years. He is diagnosed with community-acquired pneumonia and is prescribed a 7-day course of clarithromycin. Two weeks later, his family brings him to the clinic, reporting that he has become excessively sedated, confused, and unsteady on his feet.

The patient's new symptoms are most likely the result of an interaction involving which mechanism?

  1. Inhibition of CYP3A4-mediated metabolism of diazepam. (correct answer)
  2. Displacement of diazepam from plasma protein binding sites.
  3. Additive pharmacodynamic effects on the GABA-A receptor.
  4. Induction of glucuronidation pathways leading to accumulation of a toxic metabolite.
Explanation: Diazepam is extensively metabolized by cytochrome P450 enzymes, particularly CYP3A4 and CYP2C19. Clarithromycin is a potent inhibitor of CYP3A4. By inhibiting the primary metabolic pathway of diazepam, clarithromycin causes diazepam and its active metabolites (like nordiazepam) to accumulate, leading to exaggerated CNS depressant effects such as sedation, confusion, and ataxia. While protein binding displacement (B) can occur with some drugs, it is not the primary mechanism for this clinically significant interaction. The interaction is pharmacokinetic (metabolism), not pharmacodynamic (C), as clarithromycin does not act on the GABA-A receptor. Induction of metabolism (D) would decrease drug levels, not increase them, and this interaction involves inhibition, not induction.

Question 14

A patient with a significant fear of flying is prescribed a single dose of a benzodiazepine to be taken one hour before a flight. Which combination of pharmacokinetic properties would be most desirable for this specific indication?

  1. Low lipid solubility and a long elimination half-life.
  2. High lipid solubility and a short elimination half-life. (correct answer)
  3. Metabolism primarily via glucuronidation with no active metabolites.
  4. High plasma protein binding and a large volume of distribution.
Explanation: For acute, situational anxiety like fear of flying, the ideal agent should work quickly and not have lingering effects. High lipid solubility allows the drug to rapidly cross the blood-brain barrier, leading to a fast onset of action. A short elimination half-life ensures that the effects, such as sedation and cognitive impairment, will resolve relatively quickly after the flight, preventing a 'hangover' effect. Low lipid solubility (A) would delay onset. Metabolism via glucuronidation (C) is a favorable property for patients with liver disease but is not the primary determinant for this specific acute use. High protein binding and a large volume of distribution (D) are general pharmacokinetic parameters but do not specifically address the clinical need for rapid onset and short duration.

Question 15

A 60-year-old patient has been taking high doses of temazepam nightly for insomnia for over two years. Against medical advice, the patient abruptly discontinues the medication.

Which of the following potential withdrawal manifestations represents the most acute, life-threatening risk?

  1. Rebound insomnia and vivid dreams.
  2. Severe anxiety and panic attacks.
  3. Gastrointestinal distress and diaphoresis.
  4. Generalized seizures and delirium. (correct answer)
Explanation: Abrupt withdrawal from long-term, high-dose benzodiazepines or other sedative-hypnotics can lead to a severe and potentially fatal withdrawal syndrome. The most serious complications are generalized seizures, delirium, and cardiovascular collapse. While rebound insomnia (A), anxiety (B), and autonomic symptoms like GI distress and diaphoresis (C) are all common features of withdrawal, seizures pose the most immediate threat to life. Temazepam is an intermediate-acting benzodiazepine, and abrupt cessation after prolonged use carries a significant risk of severe withdrawal.

Question 16

A patient with generalized anxiety disorder has been managed on clonazepam 1 mg twice daily for several years but continues to experience significant daytime sedation. A decision is made to transition the patient to buspirone.

What is the most critical management principle during this medication transition?

  1. Clonazepam should be stopped immediately to allow buspirone to bind to 5-HT1A receptors without interference.
  2. A gradual taper of clonazepam must be initiated concurrently with buspirone initiation. (correct answer)
  3. Buspirone should be started at a high dose to rapidly replace the anxiolytic effect of clonazepam.
  4. The patient should be monitored for hypertensive crisis due to the combined serotonergic and GABAergic effects.
Explanation: Because buspirone has a delayed onset of action (2-4 weeks) and does not act on GABA receptors, it will not prevent benzodiazepine withdrawal symptoms. Therefore, when switching from a long-term benzodiazepine like clonazepam, it is essential to start buspirone and simultaneously begin a slow taper of the clonazepam. This allows buspirone's effects to begin while mitigating the risk of a severe withdrawal syndrome from clonazepam cessation. Abruptly stopping clonazepam (A) would be dangerous. Starting buspirone at a high dose (C) would increase side effects without providing immediate anxiolysis. There is no known interaction between these drugs that causes a hypertensive crisis (D).

Question 17

A patient with end-stage liver disease requires short-term management of severe anxiety related to their prognosis. The medical team wants to choose a benzodiazepine with the lowest risk of accumulation and toxicity.

The metabolism of which of the following benzodiazepines is least dependent on the hepatic cytochrome P450 system?

  1. Diazepam
  2. Chlordiazepoxide
  3. Clonazepam
  4. Oxazepam (correct answer)
Explanation: Oxazepam, along with Temazepam and Lorazepam (mnemonic 'OTL' or 'Outside The Liver'), are primarily metabolized through phase II glucuronide conjugation directly to inactive metabolites. This pathway is much less affected by liver disease or age compared to the phase I oxidative metabolism (via CYP450 enzymes) that metabolizes diazepam, chlordiazepoxide, and clonazepam. Therefore, oxazepam is a much safer choice in patients with severe hepatic impairment as it is less likely to accumulate and cause excessive sedation.

Question 18

Paradoxical reactions to benzodiazepines, such as increased agitation, aggression, and disinhibition, are a known adverse effect. Which patient population is considered to be at the highest risk for experiencing this type of reaction?

  1. Young adult males with no psychiatric history.
  2. Middle-aged females with generalized anxiety disorder.
  3. Geriatric patients with pre-existing cognitive impairment or dementia. (correct answer)
  4. Adolescents being treated for social anxiety disorder.
Explanation: While paradoxical reactions can occur in any patient, the risk is significantly higher in certain populations. The elderly, particularly those with underlying dementia, brain injury, or delirium, are most susceptible. Other high-risk groups include very young children and individuals with developmental disabilities or personality disorders. The exact mechanism is unknown but is thought to involve disinhibition of suppressed behavioral impulses. Young adults with no psychiatric history (A), middle-aged females with GAD (B), and adolescents (D) are generally considered to be at lower risk than the geriatric population with cognitive deficits.

Question 19

Chlordiazepoxide is a long-acting benzodiazepine frequently used in protocols for managing acute alcohol withdrawal syndrome.

The efficacy of chlordiazepoxide in preventing withdrawal seizures and delirium is primarily due to its ability to:

  1. Block excitatory NMDA receptors that become upregulated during chronic alcohol use.
  2. Act as a substitute for alcohol at the GABA-A receptor, mitigating the effects of GABAergic hypoactivity. (correct answer)
  3. Stimulate the release of dopamine in the nucleus accumbens, reducing cravings and dysphoria.
  4. Inhibit voltage-gated calcium channels, which stabilizes neuronal membranes against hyperexcitability.
Explanation: Chronic alcohol use enhances GABA-A receptor function. In response, the body downregulates these receptors or reduces their sensitivity. When alcohol is abruptly withdrawn, the CNS is left in a state of GABAergic hypoactivity and glutamatergic hyperactivity, leading to withdrawal symptoms like seizures. Benzodiazepines like chlordiazepoxide act on the same GABA-A receptors as alcohol. By providing a substitute source of GABAergic tone, they effectively dampen CNS hyperexcitability and allow the system to gradually re-equilibrate, preventing severe withdrawal manifestations. Benzodiazepines do not primarily block NMDA receptors (A), stimulate dopamine release in the reward pathway (C), or block voltage-gated calcium channels (D); these are mechanisms of other drugs used in addiction medicine.

Question 20

A 34-year-old female has been taking alprazolam 1 mg three times daily for panic disorder for the past year. She reports that for the last few months, she experiences a surge of intense anxiety and irritability about an hour before her next scheduled dose is due.

Which pharmacological principle best explains this patient's recurring symptoms?

  1. Pharmacodynamic tolerance to the anxiolytic effects of alprazolam.
  2. Occurrence of interdose rebound anxiety due to the drug's short half-life. (correct answer)
  3. Formation of a long-acting metabolite that has paradoxical anxiogenic effects.
  4. Downregulation of 5-HT1A receptors as a consequence of chronic GABAergic stimulation.
Explanation: The phenomenon described is interdose rebound anxiety, which is common with short-acting benzodiazepines like alprazolam. As the drug concentration falls below the therapeutic threshold between doses, withdrawal-like symptoms, including anxiety, emerge. Pharmacodynamic tolerance (A) refers to a decreased response to the drug over time, which would likely manifest as a general lack of efficacy rather than a cyclical pattern timed with dosing. Alprazolam does not have a long-acting metabolite with anxiogenic effects (C); its primary metabolites are less active and have short half-lives. Benzodiazepines do not primarily act on 5-HT1A receptors (D); their mechanism is related to GABA-A receptor modulation, and this option incorrectly links two different neurotransmitter systems.